NTAGI approves Serum Institute's Covovax for 12-17 age group
New Delhi, April 29: The National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covid-19 vaccine Covovax for the 12-17 year age group, sources said.
India's drug regulator, the Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28 last year and in the 12-17 age group with certain conditions on March 9.
On Tuesday, the DCGI approved emergency use authorisation (EUA), or restricted use in emergency situation, to three Covid vaccines for children of different age groups.
These vaccines are Bharat Biotech's Covaxin for children between the age of 6-12 years, Biological E's Covid-19 vaccine Corbevax for children of 5-12 years group, and ZycovD (Zydus Cadila vaccine) for children above the age of 12 years for a two-dose regimen.